Strs Ohio Acquires Shares of 324,000 Coherus Oncology, Inc. $CHRS

Key Points

• Strs Ohio acquired 324,000 shares of Coherus Oncology, Inc. ($CHRS), valued at approximately $261,000, making up about 0.28% of the company's stock.
• Institutional investors now own 72.82% of Coherus Oncology, reflecting significant interest from large investment firms.
• Analysts have raised Coherus Oncology's rating from "hold" to "buy" with a target price of $4.00, indicating growing confidence in the company's performance.

Strs Ohio purchased a new stake in Coherus Oncology, Inc. (NASDAQ:CHRS - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 324,000 shares of the biotechnology company's stock, valued at approximately $261,000. Strs Ohio owned approximately 0.28% of Coherus Oncology as of its most recent filing with the SEC.

Several other large investors have also recently modified their holdings of CHRS. CWM LLC raised its stake in shares of Coherus Oncology by 96.6% during the 1st quarter. CWM LLC now owns 49,793 shares of the biotechnology company's stock worth $40,000 after acquiring an additional 24,468 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its holdings in Coherus Oncology by 97.3% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 30,847 shares of the biotechnology company's stock worth $43,000 after buying an additional 15,214 shares in the last quarter. Cerity Partners LLC lifted its holdings in Coherus Oncology by 84.0% during the first quarter. Cerity Partners LLC now owns 54,676 shares of the biotechnology company's stock valued at $44,000 after purchasing an additional 24,953 shares in the last quarter. Ieq Capital LLC lifted its holdings in Coherus Oncology by 52.5% during the first quarter. Ieq Capital LLC now owns 75,020 shares of the biotechnology company's stock valued at $61,000 after purchasing an additional 25,837 shares in the last quarter. Finally, Nuveen LLC purchased a new position in shares of Coherus Oncology in the first quarter worth about $77,000. Institutional investors own 72.82% of the company's stock.

Analysts Set New Price Targets

Separately, Maxim Group raised shares of Coherus Oncology from a "hold" rating to a "buy" rating and set a $4.00 target price on the stock in a research note on Thursday, September 4th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $4.51.

Coherus Oncology Stock Up 1.3%

Shares of NASDAQ:CHRS opened at $1.58 on Thursday. The company has a market capitalization of $183.64 million, a PE ratio of 1.02 and a beta of 0.88. The company has a current ratio of 1.44, a quick ratio of 1.43 and a debt-to-equity ratio of 0.31. Coherus Oncology, Inc. has a twelve month low of $0.66 and a twelve month high of $2.43. The firm has a 50 day simple moving average of $1.14 and a 200-day simple moving average of $0.96.

About Coherus Oncology

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.

Want to see what other hedge funds are holding CHRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Coherus Oncology, Inc. (NASDAQ:CHRS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.